Why Glaukos (GKOS) Stock Is Up Today

Glaukos Corporation (GKOS) is up 5.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst appears to be renewed investor positioning after Glaukos announced on October 7, 2026 that it will release third-quarter 2026 results after market close on October 28. The move may also reflect optimism carrying over from the company’s strong second-quarter report, which showed record sales growth and higher full-year revenue guidance. This could also be because traders are anticipating another strong update for iDose TR and Epioxa.

Details:

Glaukos said in a company press release that third-quarter 2026 financial results will be released after the market closes on October 28, with a conference call scheduled the same day.

In its July 29, 2026 quarterly release, the company posted record second-quarter net sales of $185.6 million, up 50% year over year.

That same quarterly update included higher 2026 net sales guidance of $680 million to $700 million, up from the prior range of $620 million to $635 million.

The company has recently highlighted growth drivers tied to iDose TR and Epioxa, which may be supporting expectations ahead of the next earnings report.

Sources:

Glaukos investor relations, SEC, BioSpace

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GKOS Insider Trading Activity

$GKOS insiders have traded $GKOS stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.

Here’s a breakdown of recent trading of $GKOS stock by insiders over the last 6 months:

JOSEPH E GILLIAM (PRESIDENT & COO) has made 0 purchases and 3 sales selling 79,573 shares for an estimated $13,594,167.
ALEX R. THURMAN (SVP & CHIEF FINANCIAL OFFICER) has made 0 purchases and 5 sales selling 60,000 shares for an estimated $9,652,600.
TOMAS NAVRATIL (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 20 sales selling 21,162 shares for an estimated $3,522,063.
GILBERT H KLIMAN has made 0 purchases and 3 sales selling 12,500 shares for an estimated $1,853,800.
LEANA WEN has made 0 purchases and 2 sales selling 2,225 shares for an estimated $331,700.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive GKOS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$GKOS Hedge Fund Activity

We have seen 200 institutional investors add shares of $GKOS stock to their portfolio, and 132 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 752,642 shares (+inf%) to their portfolio in Q2 2026, for an estimated $105,189,245
FULLER & THALER ASSET MANAGEMENT, INC. added 529,922 shares (+inf%) to their portfolio in Q2 2026, for an estimated $74,061,898
D. E. SHAW & CO., INC. removed 501,106 shares (-89.8%) from their portfolio in Q2 2026, for an estimated $70,034,574
BALYASNY ASSET MANAGEMENT L.P. added 491,636 shares (+inf%) to their portfolio in Q2 2026, for an estimated $68,711,047
GOLDMAN SACHS GROUP INC removed 477,937 shares (-34.8%) from their portfolio in Q2 2026, for an estimated $66,796,475
BLACKROCK, INC. added 450,027 shares (+5.0%) to their portfolio in Q2 2026, for an estimated $62,895,773
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC added 446,550 shares (+inf%) to their portfolio in Q2 2026, for an estimated $62,409,827

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GKOS Government Contracts

We have seen $190,415 of award payments to $GKOS over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TRAVOPROST 75MCG: $169,104
IDOSE TRAVOPROST 75MCG IMPLANT: $21,310

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$GKOS Analyst Ratings

Wall Street analysts have issued reports on $GKOS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/10/2026

To track analyst ratings and price targets for $GKOS, check out Quiver Quantitative's $GKOS forecast page.

$GKOS Price Targets

Multiple analysts have issued price targets for $GKOS recently. We have seen 7 analysts offer price targets for $GKOS in the last 6 months, with a median target of $162.0.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $175.0 on 07/08/2026
Yi Chen from HC Wainwright & Co. set a target price of $168.0 on 07/06/2026
Adam Maeder from Piper Sandler set a target price of $165.0 on 07/01/2026
David Saxon from Needham set a target price of $150.0 on 06/17/2026
Ryan Zimmerman from BTIG set a target price of $162.0 on 06/10/2026
Larry Biegelsen from Wells Fargo set a target price of $138.0 on 04/30/2026
Allen Gong from JP Morgan set a target price of $140.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.